Targeted Radionuclide Boosts Survival in Pancreatic Tumors

A phase 2 trial of lutetium-octreotate in patients with unresectable progressive pancreatic neuroendocrine tumors shows nearly double the 1-year survival rate compared with sunitinib at standard dose.
Medscape Medical News

source https://www.medscape.com/viewarticle/982514?src=rss